1st Qtr. Earnings

Discussion in 'GlaxoSmithKline' started by Anonymous, May 4, 2015 at 6:34 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Does anyone know when we report?
     

  2. Anonymous

    Anonymous Guest

    Street will enjoy hearing that we laid off 2000 people. Bullish.
     
  3. Anonymous

    Anonymous Guest

    Go on the website and hit the search button. Come on Man! Really? Really?
     
  4. Anonymous

    Anonymous Guest

    I suppose most investors are hoping they will announce the date of this big promised special dividend
     
  5. Anonymous

    Anonymous Guest

    Another Qtr. of bad earnings and special dividend cut from 4 billion to 1 billion.

    Prediction: another 10-15% cut in the sales force and hopefully Witty and JB gone.
     
  6. Anonymous

    Anonymous Guest

    Special dividend cut from $4billion to $1Billion.
     
  7. Anonymous

    Anonymous Guest

    at least we get our quarterly bonus early this coming Friday... very nice
     
  8. Anonymous

    Anonymous Guest

    The 1st Qtr Earnings Report provided perspective on magnitude of restructuring which has been completed (versus that which is yet to be achieved).

    "In total, the Group expects all restructuring (transaction, pharmaceuticals and major change) to deliver annual cost savings benefits of £3 billion. The total cash charges to deliver these benefits are expected to be approximately £3.65 billion and the non-cash charges up to £1.35 billion. Charges to-date are £1.3 billion, predominantly cash. The delivery of the £3 billion of annual benefits is expected to be largely complete by
    the end of 2017. Going forward, the Group will report its restructuring as a single programme."

    >> So only about 25%-35% of costs to support restructuring (non-cash/cash) have been incurred.

    "The new Pharmaceuticals restructuring programme, announced in October 2014, will rescale commercial operations, global support functions and the relevant R&D/manufacturing operations across Pharmaceuticals. The programme is expected to cost £1.5 billion, predominantly in cash charges. It has delivered approximately £0.1 billion of annual savings and remains on track to deliver approximately £1 billion of annual cost savings over
    the next three years, with around 50% delivered in 2016."

    >> So only a minor portion of the annual basis of savings are being realized at this point.
     
  9. Anonymous

    Anonymous Guest

    Witty looked like a deer caught in the headlights this morning on CNBC.
     
  10. Anonymous

    Anonymous Guest

    After following Lilly driven managed care strategy for 5 years losing all kinds of volume deemed low margin by US price standards
    and then allows them to give huge discounts to get some sales back in Med D and PBM
    and now has the gall to announce a new volume strategy
    You could not dream this up never mind deliver it and get accolades from new Chair.